# ST-1898

Source: https://onco.cc/drugs/st-1898/  
OnCo record `st-1898` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ST-1898 is an experimental small molecule, multi-target tyrosine kinase inhibitor from Beijing Scitech-Mq Pharmaceuticals, in phase 2 trials for unresectable or metastatic melanoma, advanced renal cell carcinoma and radioiodine-refractory differentiated thyroid cancer and other cancers.

## Summary

ST-1898 (ACC-1898) is a small molecule (oral tablet), multi-target tyrosine kinase inhibitor from Beijing Scitech-Mq Pharmaceuticals, with AccSalus Biosciences as partner. A receptor tyrosine kinase inhibitor with multiple targets, especially VEGFR2, c-MET, AXL, PDGFRA, RET and KIT. Its furthest stage is phase 2, for unresectable or metastatic melanoma, advanced renal cell carcinoma, radioiodine-refractory differentiated thyroid cancer and hepatocellular carcinoma. ClinicalTrials.gov registers it in 4 studies linked below. Phase 2 RAIR-DTC (NCT06359847) and phase 1b/2 melanoma (NCT06359860) recruiting; phase 1b/2 RCC (NCT06127238) active not recruiting; US phase 1 as ACC-1898 (NCT07252661) not yet recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: ACC-1898
- Tags: pipeline; ctgov-ingest
- Code: ST-1898
- Modality: Small molecule (oral tablet), multi-target tyrosine kinase inhibitor
- Mechanism: A receptor tyrosine kinase inhibitor with multiple targets, especially VEGFR2, c-MET, AXL, PDGFRA, RET and KIT.

## Sources

- Beijing Scitech-Mq Pharmaceuticals: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06127238
- Beijing Scitech-Mq Pharmaceuticals: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06359847
- Beijing Scitech-Mq Pharmaceuticals: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07252661
- ClinicalTrials.gov: trials of ST-1898: https://clinicaltrials.gov/search?intr=ST-1898

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Medullary thyroid cancer](https://onco.cc/cancers/medullary-thyroid-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- targets: [AXL](https://onco.cc/targets/axl/), [KIT](https://onco.cc/targets/kit/), [MET](https://onco.cc/targets/met/), [PDGFRA](https://onco.cc/targets/pdgfra/), [RET](https://onco.cc/targets/ret/)
- companies: [AccSalus Biosciences](https://onco.cc/companies/accsalus-biosciences/), [Beijing Scitech-Mq Pharmaceuticals](https://onco.cc/companies/beijing-scitech-mq-pharmaceuticals/)
- trials: [A Study of ST-1898 for Unresectable or Metastatic Melanoma](https://onco.cc/trials/nct06359860/), [Study of ACC-1898 in Adult Participants With Advanced Solid Tumors](https://onco.cc/trials/nct07252661/), [Study of ST-1898 in Advanced Renal Cell Carcinoma](https://onco.cc/trials/nct06127238/), [Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer](https://onco.cc/trials/nct06359847/)

---
JSON: https://onco.cc/api/v1/entities/st-1898.json